CJC-1295 & Ipamorelin Blend Dosing: GH Release, Ratio and Timing

The CJC-1295 ipamorelin blend dosing describes, in preclinical research, the co-administration of two growth hormone secretagogues: a long-acting GHRH analog (CJC-1295) and a selective ghrelin-receptor agonist (Ipamorelin). Both act through separate receptor pathways and together produce a synergistic, supra-additive GH pulse. This guide frames the ratio, timing and evidence base and explicitly separates the blend from the two standalone monographs.

Why is the CJC-1295 ipamorelin blend dosing combined at all?

The core of the blend is the pharmacological synergy of two independent mechanisms. CJC-1295 is a GHRH analog and raises the basal GH level (trough), while Ipamorelin as a ghrelin-receptor mimetic triggers an additional, clean GH pulse. Because both act on different pituitary receptors, their effect does not merely add up, it potentiates.

This observation comes from classic GHRH-plus-GHRP studies. As early as 1990, Bowers and colleagues showed that the joint administration of a GH-releasing peptide and GHRH produces a GH peak far above either substance alone, and that this occurs via separate mechanisms (Bowers et al., 1990). In research on obese subjects, the combined administration of GHRH and GHRP-6 led to a massive GH discharge with a mean peak of 42.2 ng/ml (Cordido et al., 1993).

The CJC-1295 ipamorelin blend dosing transfers this principle to a pair with a particularly favorable profile: a GHRH analog with prolonged duration of action and a GHRP type that selectively releases only GH. Precisely this two-pathway logic distinguishes the blend from a mere dose increase of a single substance.

What does CJC-1295 do in the GH release peptide stack?

CJC-1295 provides the base component in the GH release peptide stack: it raises the sustained GH level. In the central human study by Teichman and colleagues, a single subcutaneous dose produced a dose-dependent GH rise of 2- to 10-fold that persisted for at least 6 days, plus an IGF-1 rise of 1.5- to 3-fold over 9 to 11 days (Teichman et al., 2006). The estimated half-life of this DAC (Drug Affinity Complex) variant was 5.8 to 8.1 days; with repeat dosing, IGF-1 remained above baseline for up to 28 days. In research the substance was best tolerated at 30 to 60 µg/kg.

Important for understanding the blend: two forms exist. The DAC variant with a long half-life, and the modified GRF(1-29), often called "no-DAC CJC-1295", with a very short half-life of around 30 minutes. Which form is used fully determines the dosing frequency: no-DAC follows pulsatile physiology and is typically applied together with Ipamorelin, whereas DAC creates a permanently elevated baseline.

This distinction is the most common error point in popular protocols. The conventional blend is almost always based on the no-DAC form, because its short kinetics match the pulse-like action of Ipamorelin.

How does Ipamorelin drive the clean GH pulse?

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 and is regarded as the first selective growth hormone secretagogue. In the foundational characterization by Raun and colleagues, it released GH with a potency comparable to GHRP-6, but with one decisive difference: Ipamorelin raised neither ACTH nor cortisol and did not affect FSH, LH, prolactin and TSH (Raun et al., 1998).

This selectivity is the actual reason Ipamorelin is preferred in blends over older GHRP types such as GHRP-6 or hexarelin. Classic GH-releasing peptides often trigger an accompanying rise in cortisol and prolactin as well as, in the case of GHRP-6, pronounced hunger. Ipamorelin delivers the GH pulse without these hormonal side pathways, which research describes as a "clean pulse".

In the blend, Ipamorelin thus takes on the role of the trigger: it generates the sharp GH spike, while CJC-1295 raises the baseline from which that spike departs. The combination of both effects is the pharmacological rationale of the stack. It remains important to note that the selectivity data come from preclinical and early clinical models and describe no therapeutic application, but the receptor profile of the substance.

What ratio does the CJC-1295 ipamorelin blend dosing typically use?

In the research literature on GHRH-plus-GHRP combinations, as well as in practitioner and community protocols, CJC-1295 (no-DAC) and Ipamorelin are frequently reported as being combined at a roughly 1:1 mass ratio. This is a convention that recurs across such protocols, not a specification derived from a controlled trial: no controlled human study has examined or validated this specific ratio.

Here is this guide's most important scientific honesty: to date (as of 2026) no published randomized controlled human trial of the specific CJC-1295 plus Ipamorelin combination exists. The popular 1:1 ratio is derived from the pharmacology of the individual components and from GHRH-plus-GHRP synergy studies, not from a direct head-to-head comparison of the two peptides.

The mechanistic rationale for a roughly equal ratio is plausible: both pathways should be engaged about equally so that the baseline effect of CJC-1295 and the pulse effect of Ipamorelin overlap maximally. Nevertheless, the concrete milligram ratio remains an extrapolation. Readers who want to understand the underlying individual substances in more detail will find the specifics in our CJC-1295 guide and in the Ipamorelin guide. For the pure arithmetic of reconstitution and concentration, the peptide calculator helps.

How does Ipamorelin CJC timing work?

The Ipamorelin CJC timing rests on a central feature of CJC-1295: it preserves natural pulsatile GH secretion. Ionescu and Frohman showed that CJC-1295 raised trough GH by about 7.5-fold and mean 24-hour GH by around 46 percent, without altering the frequency or amplitude of the GH pulses (Ionescu & Frohman, 2006). Unlike continuously delivered recombinant GH, which suppresses pituitary pulsatility, CJC-1295 leaves the body's own bursts intact.

This yields a physiological observation reported in the literature, not a usage instruction: because GH is released predominantly at night and in pulses in humans, studies describe an association between the fasted state before sleep and a more pronounced GH pulse amplitude. The underlying work describes when the body's own GH pulse tends to be strongest, not when a user should administer anything.

The observation on food intake is likewise purely descriptive. Elevated blood glucose and insulin levels after a meal dampen the GH response to secretagogues in studies, and a gap of several hours from the last carbohydrate-rich meal is repeatedly associated in the research literature with a clearer GH response. Taken together, this body of work describes a nocturnal, fasted pulse pattern of GH secretion, not a usage protocol.

Why is endogenous GHRH necessary for the synergy?

An often overlooked building block of the blend logic is the dependence of the GHRP effect on endogenous GHRH. Pombo and colleagues showed that the maximal GH response to GHRP-6 requires endogenous hypothalamic GHRH (Pombo et al., 1998). Without a sufficient GHRH background, the response of a ghrelin mimetic turns out markedly weaker.

This is exactly where the blend logic closes its loop. CJC-1295 as a GHRH analog supplies the GHRH tone that Ipamorelin needs for its full effect. The two substances therefore not only complement each other additively; one creates the precondition for the other. This is the deeper reason why a GHRH analog and a GHRP type together achieve more than the arithmetic sum.

This mutual dependence also explains why the potentiation in the synergy studies turned out so pronounced. The GHRH component lowers the activation threshold of the somatotropic cells and makes them more receptive to the ghrelin-mediated stimulus. In endocrinological terms, CJC-1295 acts permissively on the Ipamorelin response. For understanding the stack this means: the order and the joint presence of both signals is mechanistically relevant, not just the sum of two individual doses.

How does the blend differ from the individual substances?

The blend is explicitly a topic in its own right and not the sum of two monographs. The individual substance CJC-1295 is described primarily via its trough-raising, long-acting profile; the individual substance Ipamorelin via its selective, short pulse. The blend, by contrast, is defined via the combined kinetics: a raised baseline plus a sharp spike that departs from this baseline.

In practice this means three differences. First, kinetics: in the blend the no-DAC form of CJC-1295 is mostly used so that its short half-life matches the pulse logic of Ipamorelin, while the individual substance is often considered as the DAC variant with multi-day action. Second, rationale: the blend targets synergy of two receptor pathways, the individual substance a single pathway. Third, the evidence base: human studies exist for the individual substances, but not for the specific combination.

Readers who wish to consider the two building blocks separately should read the dedicated monographs to avoid cannibalizing the concepts: CJC-1295 guide and Ipamorelin guide. To place CJC-1295 against an entirely different substance class, the comparison Retatrutide vs. CJC-1295 is worthwhile, contrasting the metabolic and growth-hormone axes.

What does the CJC-1295 ipamorelin protocol say about preparation?

A CJC-1295 ipamorelin protocol is described in the research literature via reconstitution of the lyophilized powder. Peptides of this class are typically dissolved, in laboratory protocols, with bacteriostatic water, which contains benzyl alcohol as a preservative and allows longer storage of the dissolved substance. Literature on peptide handling notes that a direct water jet onto the powder can generate shear forces, which is why a gentler approach along the vial wall is commonly documented in laboratory protocols.

On stability, the literature describes the following picture: lyophilized peptide is considered stable for months at minus 20 degrees Celsius. After reconstitution, the solution is typically kept refrigerated at 2 to 8 degrees Celsius in study protocols and, in research practice, mostly used within about four weeks. Direct light exposure and repeated freezing and thawing are described in the literature as factors that diminish peptide integrity.

The concentration calculation is the most common stumbling block. If, for example, a 5 mg blend vial is reconstituted with 2 ml of bacteriostatic water, this yields a concentration of 2500 µg/ml, so that 0.1 ml of the solution contains 250 µg. This conversion of vial size, water volume and target amount can be carried out error-free with the peptide calculator. The CJC-1295 + Ipamorelin blend is currently to be treated as a research substance; this section describes laboratory handling only, no human use.

Which side effects and safety limits are documented?

The risks of sustained GH and IGF-1 elevation mirror mild acromegaly-like effects. Documented in the literature are insulin resistance and impaired glucose tolerance, fluid retention with edema, joint pain, and carpal-tunnel-type paraesthesias. Mechanistically, a GH excess blocks signaling at the insulin receptor and at IRS-1 and mobilizes free fatty acids; IGF-1 cannot overcome the GH-induced resistant state (Kim & Park, 2003).

Controllability is decisive. In supervised studies with the GHRH analog tesamorelin, IGF-1 stayed within the age-normal range, and insulin-stimulated glucose uptake was preserved (Stanley et al., 2011). Safety therefore hinges on keeping IGF-1 in the physiological window, not on uncontrolled stacking. Added to this is a theoretical tumor-growth concern, reflected in the labeled warnings of approved GHRH analogs such as tesamorelin, since IGF-1 represents a growth signal for existing cell populations.

For research, three guardrails follow: first, the consistent framing as a research substance without human use; second, the importance of IGF-1 monitoring as the central safety parameter in study models; third, the avoidance of supraphysiologic dosing. The blend potentiates the GH response by design; that is exactly why the question of the upper limit is more relevant here than with a weaker single substance.

For whom is the blend a research model, and for whom not?

As a research model, the CJC-1295 plus Ipamorelin combination is especially interesting for studying GHRH-plus-GHRP synergy. It allows two independent receptor pathways to be stimulated simultaneously in preclinical models and the resulting potentiation of GH release to be measured. The blend thus serves as a tool to study the pulsatile physiology of the somatotropic axis without suppressing the pulsatility, as exogenous recombinant GH would do.

Less suitable is the blend as a model where a clearly defined dose-response curve derived from human studies is needed. Because no randomized combination study exists, ratio and dose remain extrapolations. For questions that require a robust human evidence base, the individually studied substances are the cleaner reference.

The CJC-1295 + Ipamorelin blend is listed at BergdorfBio as a research substance and is intended exclusively for laboratory purposes. Readers who want to go deeper into the building blocks should draw on the linked individual monographs and the comparison with other substance classes to place the overall picture of growth hormone secretagogues. The decision for the blend over a single substance is ultimately a question of the research question: synergy and pulse logic on the one hand, defined single-substance kinetics on the other.

Frequently Asked Questions

Is the CJC-1295 ipamorelin blend dosing supported by human studies?

No. For the specific combination, no published randomized controlled human trial exists as of 2026. The common 1:1 ratio is derived from the pharmacology of the individual substances and from GHRH-plus-GHRP synergy studies, not from a direct combination comparison.

Why is no-DAC rather than DAC CJC-1295 mostly used in the blend?

Because the no-DAC form (modified GRF(1-29)) has a short half-life of around 30 minutes and thus matches the pulse-like action of Ipamorelin. The DAC variant, with a 5.8- to 8.1-day half-life, by contrast creates a permanent baseline and follows a different frequency logic.

Why is the timing placed in the fasted state before sleep?

Because studies show GH is released predominantly at night and in pulses in humans, and CJC-1295 preserves this natural pulsatility. Elevated insulin and glucose levels after a meal additionally dampen the GH response in study models. This is a physiological observation from research, not a usage instruction.

What is the most important safety parameter?

IGF-1. In controlled studies with GHRH analogs, glucose uptake was preserved as long as IGF-1 stayed within the age-normal range. Persistently supraphysiologic IGF-1 is associated with insulin resistance, edema and a theoretical tumor-growth concern.

Does the blend replace the individual guides on CJC-1295 and Ipamorelin?

No. This guide explicitly covers co-administration, the ratio and the combined GH pulse. For the kinetics, receptor profile and evidence base of each individual substance, the CJC-1295 guide and the Ipamorelin guide are the appropriate references.

For research purposes only. Not intended for human consumption. Scientific editing: Dr. Sieglinde Klaus